All In Biotech

Drug Trial Radar · NCT06997497

A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084, Cetuximab, and mFOLFOX6 Versus mFOLFOX6 With or Without Bevacizumab as First-line Treatment of Participants With KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer (KANDLELIT-012)

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 477 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

477

Planned (sponsor's estimate)

Start

Jul 16, 2025

Primary completion

Mar 28, 2029

Study completion Oct 27, 2030

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
May 30, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for other ways to treat locally advanced or metastatic colorectal cancer (mCRC) that is unresectable and has a gene mutation called KRAS G12C. Standard (or usual) treatments for this type of colorectal cancer may include mFOLFOX6 with or without bevacizumab. Researchers want to learn if adding calderasib (the study medicine) and cetuximab to mFOLFOX6 can treat locally advanced or mCRC with the KRAS G12C mutation. Calderasib and cetuximab are targeted therapies. The goals of this study are to learn: * About the safety of calderasib with cetuximab and mFOLFOX6 and if people tolerate the treatments * If people who receive calderasib with cetuximab and mFOLFOX6 live longer without mCRC growing or spreading compared to people who receive mFOLFOX6 with or without bevacizumab.

Conditions

  • Colon Adenocarcinoma
  • Rectal Adenocarcinoma

Interventions

  • CalderasibDrug

    Oral tablet

  • OxaliplatinDrug

    Per label

  • Leucovorin/levofolinate calciumDrug

    Per label

  • 5-FluorouracilDrug

    Per label

  • CetuximabBiological

    Per label

  • BevacizumabDrug

    Per label

  • Bevacizumab biosimilarDrug

    Per label

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Experiencing Dose-Limiting Toxicity (DLT)Time frame: Up to approximately 28 days
  2. Part 1: Number of Participants Who Experience an Adverse Event (AE)Time frame: Up to approximately 44 months
  3. Part 1: Number of Participants Who Discontinue Study Treatment Due to an AETime frame: Up to approximately 44 months
  4. Progression Free Survival (PFS)Time frame: Up to approximately 44 months

Locations

247 sites in 29 countries. Site status is shown where the registry gives one.

  • Mayo Clinic - Arizona ( Site 0090)

    Phoenix, Arizona · Recruiting

  • Orange Coast Memorial Medical Center ( Site 2007)

    Fountain Valley, California · Recruiting

  • Los Angeles Hematology Oncology Medical Group ( Site 0084)

    Los Angeles, California · Recruiting

  • University of California Davis (UC Davis) Comprehensive Cancer Center ( Site 2021)

    Sacramento, California · Recruiting

  • UCLA Hematology/Oncology - Santa Monica ( Site 0088)

    Santa Monica, California · Recruiting

  • University of Colorado Health - Harmony-Cancer Care and Hematology - Ft. Collins ( Site 0087)

    Fort Collins, Colorado · Recruiting

  • Rocky Mountain Cancer Centers (RMCC) ( Site 8000)

    Lone Tree, Colorado · Recruiting

  • Florida Cancer Specialists - South ( Site 7002)

    Fort Myers, Florida · Recruiting

  • Mayo Clinic in Florida ( Site 0092)

    Jacksonville, Florida · Recruiting

  • Orlando Health Cancer Institute ( Site 0065)

    Orlando, Florida · Recruiting

  • Florida Cancer Specialists - North ( Site 7001)

    St. Petersburg, Florida · Recruiting

  • Florida Cancer Specialists - East ( Site 7000)

    West Palm Beach, Florida · Recruiting

  • Piedmont Atlanta Hospital ( Site 2002)

    Atlanta, Georgia · Recruiting

  • Saint Alphonsus Regional Medical Center ( Site 0085)

    Boise, Idaho · Recruiting

  • Endeavor Health ( Site 2027)

    Evanston, Illinois · Recruiting

  • Accellacare of Duly ( Site 2015)

    Lisle, Illinois · Recruiting

  • Franciscan Health ( Site 2025)

    Indianapolis, Indiana · Recruiting

  • University of Iowa ( Site 0074)

    Iowa City, Iowa · Recruiting

  • University of Kentucky ( Site 0055)

    Lexington, Kentucky · Recruiting

  • Norton Cancer Institute, Audubon Hospital Campus ( Site 0054)

    Louisville, Kentucky · Recruiting

  • University of Maryland ( Site 2016)

    Baltimore, Maryland · Recruiting

  • Greater Baltimore Medical Center ( Site 0068)

    Baltimore, Maryland · Recruiting

  • Mayo Clinic in Rochester, Minnesota ( Site 0091)

    Rochester, Minnesota · Recruiting

  • Hattiesburg Clinic ( Site 0064)

    Hattiesburg, Mississippi · Recruiting

  • Saint Luke's Cancer Institute ( Site 0082)

    Kansas City, Missouri · Recruiting

  • Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana ( Site 2000)

    Billings, Montana · Recruiting

  • University Of Nebraska Medical Center ( Site 0078)

    Omaha, Nebraska · Recruiting

  • Comprehensive Cancer Centers of Nevada ( Site 2026)

    Las Vegas, Nevada · Recruiting

  • Renown Regional Medical Center ( Site 0056)

    Reno, Nevada · Recruiting

  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 0060)

    Hackensack, New Jersey · Recruiting

  • Atlantic Health System ( Site 0093)

    Summit, New Jersey · Recruiting

  • San Juan Oncology Associates, P.C ( Site 2011)

    Farmington, New Mexico · Recruiting

  • Memorial Sloan Kettering Cancer Center ( Site 0095)

    New York, New York · Recruiting

  • Ellis Hospital ( Site 0098)

    Schenectady, New York · Recruiting

  • WakeMed Raleigh Campus ( Site 0094)

    Raleigh, North Carolina · Recruiting

  • Miami Valley Hospital South ( Site 0075)

    Centerville, Ohio · Recruiting

  • University of Cincinnati Medical Center ( Site 2005)

    Cincinnati, Ohio · Recruiting

  • University of Toledo Medical Center ( Site 2001)

    Toledo, Ohio · Recruiting

  • St. Luke's University Health Network ( Site 2014)

    Easton, Pennsylvania · Recruiting

  • UPMC Hillman Cancer Center ( Site 2024)

    Pittsburgh, Pennsylvania · Recruiting

Showing 40 of 247 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.